Main Logo
PFS

Kerri FitzgeraldChronic Lymphocytic Leukemia | February 1, 2023
Updated findings from the ASCEND study were presented at the 2022 ASCO Annual Meeting.
Read More
Ariel DeMaioMyeloma | November 14, 2022
Findings support the use of MRD negativity as a prognostic tool to measure deep response, leading to improved PFS.